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Background 
Beta-blockers refer to an assorted group of medications that block the action of 
endogenous catecholamines on beta-adrenergic receptors.1 The ß 1 and ß 2 receptors
are the primary beta-adrenergic receptors in the human cardiovascular system. Beta- 
blockers differ in their ß 1/ ß2-receptor selectivity and vasodilatory properties. Based 
on this diversity, beta-blockers have been categorised into first, second and third 
generation. First-generation beta-blockers, also referred to as non-selective blockers, 
possess equal affinity for ß1 and ß2 receptors. Second-generation (or selective) beta-
blockers exercise more affinity for ß1 than ß2 receptors. Neither of these traditional 
beta-blockers has vasodilatory properties, which is an intrinsic characteristic of third-
generation beta-blockers.2
Beta-blockers have been known to play a  role  in  blood  pressure  control  since 1949.3
We  summarise  the  findings  of  a Cochrane Review we published in 2017 on the 
comparative effects of beta-blockers as initial treatment for hypertension.4 This is an
update of a review we first published 10 years ago.5–7
Concise methods 
We searched the Cochrane Library, MEDLINE, EMBASE and ClinicalTrials. gov using a 
comprehensive database-specific search string and checked reference lists of relevant 
publications, up to June 2016. We selected randomised trials with a duration of at 
least 12 months, which assessed the effects of beta-blockers as first-line therapy for 
hypertension, compared with placebo or other antihypertensive drugs. Eligible studies 
had to report one or more of the following outcomes: all-cause mortality, stroke, 
coronary heart disease, cardiovascular death and cardiovascular events (ie, coronary 
heart disease, strokes and heart failure). We used standard Cochrane methods to 
select eligible studies, assess risk of bias, extract and analyse data and assess the 
certainty of the evidence.7
Main results 
Thirteen studies met our inclusion criteria. These studies compared beta-blockers 
with placebo or no treatment (four   studies),   diuretics   (five   studies), calcium-
2 
 
channel blockers (four studies) and renin–angiotensin system inhibitors (three studies). 
Ten studies enrolled both men and women and the rest enrolled only men. Six studies 
enrolled participants aged 65 years or younger and the others enrolled participants aged 
18 to 70 years (one study), 40 to 79 years (one study), 45 to 75 years (one study), more 
than 50 years (one study), 55 to 80 years (one study), 60 to 79 years (study) and 65 to 74 
years (one study). 
 
Most studies were conducted in Western Europe and North America. Among the nine 
studies that provided data on race, the proportion of participants categorised as white 
was 0% (one study), 44% to 48% (two studies) and 86% to 100% (six studies). We 
adjudicated most studies to have a high risk of bias because of weaknesses in study 
design, conduct and data analysis. 
 
Table 1 shows the summary of beta-blocker effects on key outcomes. When used as initial 
treatment for hypertension, there is low-certainty evidence that beta-blockers may reduce 
the risk of cardiovascular events compared with placebo. This beneficial effect is a 
reflection of the substantial reduction in strokes with beta-blockers since there is little or 
no difference in coronary events between patients on beta-blockers and those on placebo. 
There is moderate-certainty evidence that this effect of beta-blockers on cardiovascular 
events is similar to that of diuretics and renin–angiotensin system inhibitors, but it is 
inferior to that of calcium-channel blockers. In addition, there is moderate-certainty 
evidence that calcium-channel blockers and renin– angiotensin system inhibitors prevent 
strokes more than beta-blockers. However, there is moderate-certainty evidence that 
beta-blockers have little or no effect on all-cause mortality when used as initial treatment 
for hypertension. This effect of beta-blockers on mortality is identical to that of diuretics 
and renin–angiotensin system inhibitors, but it is inferior to that of calcium-channel 
blockers. Finally, there is low-certainty evidence that hypertensive patients on beta-
blockers are more likely to discontinue medications due to adverse events than patients 
on renin–angiotensin system inhibitors. Nonetheless, there is little or no difference in 
adverse events between beta-blockers and diuretics or calcium-channel blockers. 
 
Overall, treatment of hypertension leads to reductions in cardiovascular events with the 
degree of reduction dependent on the type of medication used to initiate treatment. 
Starting therapy with calcium-channel blockers or renin–angiotensin system inhibitors 
produces higher declines in cardiovascular events than with beta-blockers. 
 
Limitations 
All included studies added other antihypertensive medications to the initial therapy. 
Thus, it is possible that the suboptimal effects seen with first-line beta-blockers could 
have resulted from the additional medications used. Atenolol (a second-generation or 
selective beta-blocker) was the beta-blocker used in three-quarters of participants in 
beta-blocker arms. Thus, it is not possible to say whether the suboptimal effectiveness 
and safety seen with beta-blockers is a property of atenolol or is a class effect of all beta-




in preventing mortality or cardiovascular events. The certainty of the evidence for most 
outcomes was low, implying that the likelihood of further research finding the effect of 
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